Enrollment Complete in Phase 1/2 Trial of Batten-1 for CLN3 Disease
Theranexus and the Beyond Batten Disease Foundation (BBDF) have completed enrollment for a Phase 1/2 clinical trial testing Batten-1 — the partners’ revamped experimental therapy, solely containing miglustat — in adolescents and adults with juvenile Batten disease. This is “an important milestone in the development of Batten-1, a…